John Greene Buys 7,000 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) Director John Greene acquired 7,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, February 26th. The shares were purchased at an average price of $44.85 per share, with a total value of $313,950.00. Following the purchase, the director now owns 7,000 shares in the company, valued at $313,950. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

CRISPR Therapeutics Stock Up 0.7 %

Shares of NASDAQ CRSP opened at $43.92 on Friday. The firm has a 50-day simple moving average of $42.42 and a 200-day simple moving average of $45.97. The stock has a market capitalization of $3.77 billion, a price-to-earnings ratio of -10.05 and a beta of 1.67. CRISPR Therapeutics AG has a 52 week low of $36.52 and a 52 week high of $89.88.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, equities research analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research report on Thursday, February 13th. Barclays boosted their target price on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 12th. Bank of America dropped their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Citigroup dropped their target price on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating on the stock in a research report on Tuesday, February 18th. Finally, TD Cowen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price objective on the stock in a report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $74.40.

Institutional Investors Weigh In On CRISPR Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Boston Family Office LLC increased its position in CRISPR Therapeutics by 2.2% during the third quarter. Boston Family Office LLC now owns 9,763 shares of the company’s stock worth $459,000 after purchasing an additional 213 shares during the last quarter. Bedell Frazier Investment Counselling LLC boosted its stake in CRISPR Therapeutics by 0.8% during the third quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company’s stock worth $1,238,000 after buying an additional 218 shares during the period. The Manufacturers Life Insurance Company boosted its stake in CRISPR Therapeutics by 1.9% during the third quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company’s stock worth $586,000 after buying an additional 231 shares during the period. Intellectus Partners LLC boosted its stake in CRISPR Therapeutics by 3.6% during the fourth quarter. Intellectus Partners LLC now owns 7,131 shares of the company’s stock worth $281,000 after buying an additional 250 shares during the period. Finally, Farrow Financial Inc. boosted its stake in CRISPR Therapeutics by 1.4% during the fourth quarter. Farrow Financial Inc. now owns 20,097 shares of the company’s stock worth $777,000 after buying an additional 270 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.